The Impact of LEP rs7799039 Polymorphism and Obesity on the Severity of Coronavirus Disease-19

References

• Mohamed AA, Mohamed N, Mohamoud S, et al. SARS-CoV-2: the path of prevention and control. Infect Disord Drug Targets. 2020;20:1–5. doi:10.2174/1871526520666200520112848
   Google Scholar
• Mohamed AA, Mohamed N, Abd-Elsalam S, et al. COVID-19 in pediatrics: a diagnostic challenge. Curr Pediatr Rev. 2021;17:225–228. doi:10.2174/1573396317666210329153515
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of f coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032
   PubMed Web of Science ®Google Scholar
• Alberca RW, Oliveira LM, Branco ACCC, Pereira NZ, Sato MN. Obesity as a risk factor for COVID-19: an overview. Crit Rev Food Sci Nutr. 2020:1–15. PMID: 32539446. doi:10.1080/10408398.2020.1775546
   Web of Science ®Google Scholar
• Gao F, Zheng KI, Wang XB, et al. obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020;43(7):e72–e74. PMID: 32409499. doi:10.2337/dc20-0682
   PubMed Web of Science ®Google Scholar
• Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71(15):896–897. doi:10.1093/cid/ciaa415
   PubMed Web of Science ®Google Scholar
• Aboulghate M, Elaghoury A, Elebrashy I, et al. The burden of obesity in Egypt. Front Public Health. 2021;9:718978. doi:10.3389/fpubh.2021.718978
   PubMed Web of Science ®Google Scholar
• Mohammad S, Aziz R, Al Mahri S, et al. Obesity and COVID-19: what makes obese host so vulnerable? Immun Ageing. 2021;18(1):1. doi:10.1186/s12979-020-00212-x
   PubMed Web of Science ®Google Scholar
• Munzberg H, Morrison CD. Structure, production and signaling of leptin. Metabolism. 2015;64(1):13–23.
   PubMed Web of Science ®Google Scholar
• Haidong W, Wang C, Han W, et al. Association of leptin and leptin receptor polymorphisms with coronary artery disease in a North Chinese Han population. Rev Soc Bras Med Trop. 2020;53:e20190388.
   PubMed Web of Science ®Google Scholar
• Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation. 2008;117(25)):3238–3249. doi:10.1161/CIRCULATIONAHA.107.741645
   PubMed Web of Science ®Google Scholar
• Singla P, Bardoloi A, Parkash A. Metabolic effects of obesity: a review. World J Diabetes. 2010;1:76–88. doi:10.4239/wjd.v1.i3.76
   PubMedGoogle Scholar
• Saucillo DC, Gerriets VA, Sheng J, Rathmell JC, Maciver NJ. Leptin metabolically licenses T cells for activation to link nutrition and immunity. J Immunol. 2014;192(1):136–144. doi:10.4049/jimmunol.1301158
   PubMed Web of Science ®Google Scholar
• van der Weerd K, Dik WA, Schrijver B, et al. Morbidly obese human subjects have increased peripheral blood CD4+ T cells with skewing toward a Treg- and Th2-dominated phenotype. Diabetes. 2012;61(2):401–408. doi:10.2337/db11-1065
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Ackerman SE, Shen L, Engleman E. Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest. 2017;127(1):5–13. doi:10.1172/JCI88876
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Liu LF, Lamendola C, et al. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler Thromb Vasc Biol. 2014;34(12):2637–2643. doi:10.1161/ATVBAHA.114.304636
   PubMed Web of Science ®Google Scholar
• Ryan PM, Caplice NM. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? Obesity. 2020;28(7):1191–1194. doi:10.1002/oby.22843
   PubMed Web of Science ®Google Scholar
• Maier HE, Lopez R, Sanchez N, et al. Obesity increases the duration of influenza A virus shedding in adults. J Infect Dis. 2018;218(9):1378–1382. doi:10.1093/infdis/jiy370
   PubMed Web of Science ®Google Scholar
• Grantham M, Pantelic J, Bueno de mesquite PJ, et al. Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community. Proc Natl Acad Sci U S A. 2018;115(5):1081–1086. doi:10.1073/pnas.1716561115
   PubMed Web of Science ®Google Scholar
• Luzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. Acta Diabetol. 2020;57(6):759–764. doi:10.1007/s00592-020-01522-8
   PubMed Web of Science ®Google Scholar
• Zolfaghari Emameh R, Falak R, Bahreini E. Application of system biology to explore the association of neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2. Biol Proced Online. 2020;22:11. doi:10.1186/s12575-020-00124-6
   PubMed Web of Science ®Google Scholar
• Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428–455. doi:10.1111/all.14657
   PubMed Web of Science ®Google Scholar
• Buscemi S, Corleo D, Randazzo C. Risk factors for COVID-19: diabetes, hypertension, and obesity. Adv Exp Med Biol. 2021;1353:115–129.
   PubMedGoogle Scholar
• Zolfaghari Emameh R, Nosrati H, Eftekhari M, et al. Expansion of single cell transcriptomics data of SARS-CoV infection in human bronchial epithelial cells to COVID-19. Biol Proced Online. 2020;22:16. doi:10.1186/s12575-020-00127-3
   PubMed Web of Science ®Google Scholar
• Khorramdelazad H, Kazemi MH, Najafi A, et al. Immunopathological similarities between COVID-19 and influenza: investigating the consequences of co-infection. Microb Pathog. 2021;152:104554. doi:10.1016/j.micpath.2020.104554
   PubMed Web of Science ®Google Scholar
• Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318:E736–E741. doi:10.1152/ajpendo.00124.2020
   PubMed Web of Science ®Google Scholar
• Sattar N, Mcinnes IB, Mcmurray JJV. obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation. 2020;142(1):4–6. immune activation, and cytokine amplification in coronavirus disease 2019? Obesity; 28(7):1191–1194. doi:10.1161/CIRCULATIONAHA.120.047659
   PubMed Web of Science ®Google Scholar
• Goumenou M, Sarigiannis D, Tsatsakis A, et al. COVID 19 in Northern Italy: an integrative overview of factors possibly influencing the sharp increase of the outbreak (review). Mol Med Rep. 2020;22:20–32. doi:10.3892/mmr.2020.11079
   PubMed Web of Science ®Google Scholar
• Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of COVID-19 in New York city. N Engl J Med. 2020;382:2372e4. doi:10.1056/NEJMc2010419
   Web of Science ®Google Scholar
• Palaiodimos L, Chamorro-Pareja N, Karamanis D, et al. Diabetes is associated with increased risk for inhospital mortality in patients with COVID-19: a systematic review and meta-analysis comprising 18,506 patients. Hormones. 2020;20:305–314.
   PubMedGoogle Scholar
• Memtsoudis SG, Ivascu NS, Pryor KO, Goldstein PA. Obesity as a risk factor for poor outcome in COVID-19-induced lung injury: the potential role of undiagnosed obstructive sleep apnoea. Br J Anaesth. 2020;125(2):e262–e263. doi:10.1016/j.bja.2020.04.078
   PubMed Web of Science ®Google Scholar
• Sheervalilou R, Shirvaliloo M, Sargazi S, et al. Application of nanobiotechnology for early diagnosis of SARS-CoV-2 infection in the COVID-19 pandemic. Appl Microbiol Biotechnol. 2021;105(7):2615–2624. doi:10.1007/s00253-021-11197-y
   PubMed Web of Science ®Google Scholar
• Abdelmoemen G, Khodeir SA, Zaki AN, et al. Overexpression of hepassocin in diabetic patients with nonalcoholic fatty liver disease may facilitate increased hepatic lipid accumulation. Endocr Metab Immune Disord Drug Targets. 2019;19(2):185–188. doi:10.2174/1871530318666180716100543
   PubMed Web of Science ®Google Scholar
• COVIDSurg Collaborative; GlobalSurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. Anaesthesia. 2022;77(1):28–39.
   PubMed Web of Science ®Google Scholar
• Sheervalilou R, Shirvaliloo M, Sargazi S, et al. Convalescent blood: current perspective on the efficacy of a legacy approach in COVID-19 treatment. Blood Purif. 2022;51(1):1–14. doi:10.1159/000513164
   PubMed Web of Science ®Google Scholar
• Abd-Elsalam S, Salama M, Soliman S, et al. Remdesivir efficacy in COVID-19 treatment: a randomized controlled trial. Am J Trop Med Hyg. 2021;106(3):886–890. doi:10.4269/ajtmh.21-0606
   PubMed Web of Science ®Google Scholar
• Heidari Nia M, Rokni M, Mirinejad S, et al. Association of polymorphisms in tumor necrosis factors with SARS-CoV-2 infection and mortality rate: a case-control study and in silico analyses. J Med Virol. 2022;94(4):1502–1512. doi:10.1002/jmv.27477
   PubMed Web of Science ®Google Scholar
• Sargazi S, Sheervalilou R, Rokni M, et al. The role of autophagy in controlling SARS-CoV-2 infection: an overview on virophagy-mediated molecular drug targets. Cell Biol Int. 2021;45:1599–1612. doi:10.1002/cbin.11609
   PubMed Web of Science ®Google Scholar
• Rokni M, Heidari Nia M, Sarhadi M, et al. Association of TMPRSS2 gene polymorphisms with COVID-19 severity and mortality: a case-control study with computational analyses. Appl Biochem Biotechnol. 2022;194(8):3507–3526. doi:10.1007/s12010-022-03885-w
   PubMed Web of Science ®Google Scholar